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Background: Adoption of new technology in both basic research and clinical settings requires rigorous validation
of analytical performance. The OncoScan® FFPE Assay is a multiplexing tool that offers genome-wide copy number
and loss of heterozygosity detection, as well as identification of frequently tested somatic mutations.
Methods: In this study, 162 formalin fixed paraffin embedded samples, representing six different tumour types,
were profiled in triplicate across three independent laboratories. OncoScan® formalin fixed paraffin embedded assay
data was then analysed for reproducibility of genome-wide copy number, loss of heterozygosity and somatic
mutations. Where available, somatic mutation data was compared to data from orthogonal technologies
(pyro/sanger sequencing).
Results: Cross site comparisons of genome-wide copy number and loss of heterozygosity profiles showed greater
than 95% average agreement between sites. Somatic mutations pre-validated by orthogonal technologies showed
greater than 90% agreement with OncoScan® somatic mutation calls and somatic mutation concordance between
sites averaged 97%.
Conclusions: Reproducibility of whole-genome copy number, loss of heterozygosity and somatic mutation data
using the OncoScan® assay has been demonstrated with comparatively low DNA inputs from a range of highly
degraded formalin fixed paraffin embedded samples. In addition, our data shows examples of clinically-relevant
aberrations that demonstrate the potential utility of the OncoScan® assay as a robust clinical tool for guiding
tumour therapy.
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Formalin fixed paraffin embedded (FFPE) samples repre-
sent approximately 80-90% of all archived solid tumours
with more than a billion samples stored in hospitals and
tissue banks across the globe [1]. FFPE samples have
been historically used for microscopic analysis of tumour
material. Fixation of tissues is undertaken under very
variable conditions and in most is satisfactory for routine
assessments. The genetic profiling of FFPE samples
provides valuable clinical information for diagnosis,* Correspondence: Joseph_Foster@affymetrix.com
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unless otherwise stated.prognosis and prediction of treatment outcomes. Unfor-
tunately nucleic acids and other macromolecules suffer
considerable deterioration in quantity and quality as a
result of the routine FFPE process [2], complicating any
downstream molecular assay. Characteristics of DNA
isolated from FFPE are short fragment length, DNA-
protein crosslinks and base damage [3]. The problem of
utilising FFPE samples is further compounded by the
limited amount of DNA that can be extracted. These in-
herent features of DNA extracted from FFPE tissue can
lead to assay failure, errors in amplification and sequen-
cing, and subsequent misinterpretation of results sinceThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sufficient quantities of DNA isolated from fresh tissue.
The OncoScan® FFPE Assay Kit (OncoScan® assay) has
been optimised for whole genome copy number (CN),
loss of heterozygosity (LOH) and somatic mutation
(SM) detection from highly degraded FFPE samples.
Based on molecular inversion Probe (MIP) [4] technol-
ogy, this SNP assay provides whole genome coverage
with increased resolution in approximately 900 cancer
genes while also currently detecting 74 clinically action-
able SMs commonly found in 9 cancer genes. The assay
requires ≤ 80ng of input DNA and can utilise extremely
degraded DNA, with probes having a genomic footprint
of just 40bp, making it ideally suited to FPPE samples.
The OncoScan® assay has been adopted in a number of
research and translational laboratories and its utility
across a range of tumour types reported [5-8].
The importance and value of whole genome CN data
has been underestimated when regarding the future of
clinical practice for the guidance of tumour therapy [9].
Recent literature describes a growing occurrence of copy
number aberrations with both prognostic [10], diagnos-
tic and therapy prediction value. It has recently been
suggested that CN rather than SM may be of greater im-
portance to guiding therapeutics in certain tumour types
due to the availability of drugs that target copy number
aberrations [11]. Analysis of TCGA datasets has revealed
that several solid tumours are driven by copy number
rather than by somatic mutations. These have been des-
ignated “C class tumours” and include ovarian cancer,
breast cancer, squamous cell lung cancer, head and neck
cancers [11]. Whole genome approaches to CN profiling
potentially offer considerable advantages in the detection
of diverse clinically actionable aberrations over more
established single locus, lower resolution targeted tests
such as FISH. Currently, there are well defined molecular
signatures associated with particular tumour types e.g.
HER2 amplification (with or without TOP2A amplifica-
tion) in breast cancer. However, as more whole genome
CN data is collected, the same signatures, albeit at a differ-
ing frequency, are being found in a range of tumour types
[12,13]. This questions the efficiency of current methods
that target only a handful of common aberrations in spe-
cific tumour types and points to the need for wider profil-
ing of clinically-relevant aberrations regardless of tumour
type. Technology platform aside, it is expected that whole
genome CN data, in combination with SM information,
will play an important role in both basic research and the
future of clinical practice [11].
This study aims to evaluate the reproducibility of all
aspects of the OncoScan® assay and where orthogonal
pre-validation of SM data is already freely available, esti-
mate the platform’s SM sensitivity. 162 FFPE tumour
samples covering six different tissue types were collectedand each run on the OncoScan® assay in triplicate across
three independent laboratories. Quality Control (QC)
metrics, CN, LOH and SM results were compared across
the laboratories and SM data compared with results
from orthogonal technologies. From these samples we
have identified numerous examples of clinically-relevant
aberrations that highlight the benefits of combined
whole genome CN, LOH and SM approaches in various
tissue types which are illustrated and discussed.
Methods
A collection of 162 FFPE tissue samples of colorectal,
breast, ovarian, melanoma, prostate and lung cancers
were obtained through West Midlands Regional Genetics
Laboratory (WMRGL) from the Human Biomaterials
Resource Centre at the University of Birmingham and from
the Leeds Institute of Cancer Pathology (LICAP). Samples
sourced at WMRGL were collected through the University
of Birmingham’s Human Biomaterials Resource Centre
(HBRC), an HTA-licensed facility dedicated to the
collection, processing and storage of appropriately
consented, high quality human biomaterials for
research. The HBRC is ethically approved (North
West 5 Research Ethics Committee, Haydock Park;
Ref 09/H1010/75) and so samples may be released to
this study without the requirement for project-specific
ethical approval. The HBRC has been supported
through Birmingham Science City - Experimental
Medicine Network of Excellence project. Samples
sourced at LICAP were ethically approved by NRES
Committee North East - York for use under the study title
“Prognostic and predictive factors in Colorectal Cancer”;
Ref 08/H0903/62. It is for the purpose of evaluating the
real-world reproducibility of OncoScan® that we do not
mandate the protocol upstream of the OncoScan® assay.
The FFPE blocks were up to 23 years old. With a variety
of sample handling/preparation techniques, we believe
this dataset well represents the diversity of FFPE tumour
material available in the clinic and sample repositories.
For Colorectal samples collected at LICAP and Lung
samples collected from WMRGL five to ten sections
(scrolls), each 5 to 6 μm thick, were cut from the FFPE
blocks. The FFPE scrolls were mounted on to Superfrost
slides, a single slide was stained with haematoxylin and
eosin to identify tumour enriched regions and was used as
a template for the macrodissection of this region from the
unstained slides. The tumour-enriched region of the
remaining scrolls of colorectal and lung cancer was cut
and deposited into a 1.5 ml Eppendorf tube for
DNA extraction. For all the other tumour types used
in this study which were collected at WMRGL,
macrodissection of tumour enriched region was not
performed; rather the entire scroll was used for
DNA extraction. DNA was extracted using QIAamp
Foster et al. BMC Medical Genomics  (2015) 8:5 Page 3 of 13DNA FFPE Tissue Kit (QIAGEN) following the
manufacturer recommended protocol and according to
the Standard Operating Procedure (SOP) of each lab.
DNA was quantified using the Quant-iT™ PicoGreen®
dsDNA Assay Kit (Life Technologies) following the
manufacturer’s recommended protocol. The concentra-
tion of the DNA stock was adjusted to 12 ng/μl using
reduced EDTA TE buffer (10 mM Tris-HCl, 0.1 mM dis-
odium EDTA, pH 8) or by vacuum evaporation depend-
ing on the starting concentration. In preparation for the
assay the 12 ng/μl DNA was plated at 6.6 μl/well (giving
a total of 79.2 ng DNA/well) in MicroAmp Optical 96-
well reaction plates (Life Technologies); this was done in
triplicate to provide each of the three test laboratories
with enough DNA to run the assay. The DNA plates
were sealed with Micro-Amp Clear Adhesive Film
(Applied Biosystems) and kept frozen at -20°C. Two
plates were shipped to the other laboratories on dry
ice and the third plate was kept frozen at the sample
origin laboratory until required for the assay. Five
Plates containing 56 DNA samples were sent out from
LICAP to WMRGL and Almac Diagnostics (Almac)
and seven plates containing 106 DNA samples were
sent from WMRGL to LICAP and Almac.
The OncoScan® assay utilizes the MIP technology, for
the identification of CN alterations, LOH and SMs. MIP
probes in the OncoScan® assay capture the alleles of over
220,000 SNPs at carefully selected genomic locations,
distributed across the genome with increased probe
density within ~900 cancer genes. Furthermore, the MIP
probes also enable detection of 74 frequently tested
somatic mutations in nine genes implicated in cancer
(BRAF, KRAS, EGFR, IDH1, IDH2, PTEN, PIK3CA,
NRAS and TP53).
Cross-laboratory comparison of the OncoScan® (Affy-
metrix Inc) assay’s performance was evaluated by run-
ning the assay at the three test laboratories on plates
containing the same set of samples and by following the
recommended protocol outlined in the OncoScan® assay
manual. In short, the copy number and somatic muta-
tion MIP probes were added to the FFPE DNA in each
well and allowed to anneal at 58°C overnight (16-18h)
after an initial denaturation at 95°C for 5 min. Each sam-
ple was then split into two wells and gap fill reaction
was performed by adding dATP (A) and dTTP (T) (A/T)
in one well and dGTP (G) and dCTP (C) (G/C) to the
other well. Uncircularised MIP probes and genomic
DNA were digested by using a cocktail of exonucleases,
leaving only MIP probes that have been gap filled by the
A/T or G/C nucleotides. The circular MIP probes were
then linearized using a cleavage enzyme and amplified
by PCR. Following a second round of PCR amplification
the 120bp amplicons were cleaved into two fragments
with the Haeiii enzyme, of which the smaller (44bp)fragment is to be hybridized onto the OncoScan® assay
arrays. Samples were then mixed with hybridization buf-
fer and injected into the OncoScan® assay arrays where
they were allowed to hybridize for 16-18 h. At the end
of the hybridization period, arrays were stained and
washed using the GeneChip® Fluidics Station 450 and
loaded into the GeneChip® Scanner 3000 7G (Affyme-
trix) where array fluorescence intensity was scanned to
generate array images (DAT file). Array fluorescence in-
tensity (CEL) files were automatically generated from
DAT files by the Affymetrix® GeneChip® Command Con-
sole® (AGCC) Software version 4.0. By following the
manufacturer’s recommended protocol we were able to
complete an OncoScan® assay run, of up to 46 samples
(plus positive and negative controls) over a 48-hour
period.
In total, 162 unique samples were collected from two
laboratories; LICAP and WMRGL and pre-validated for
a set of somatic mutations (SMs) via a wide range of
technologies at the laboratory they were sourced from
(See Additional file 1: Table S1).
Array fluorescence intensity data (CEL files), gener-
ated by Affymetrix® GeneChip® Command Console®
(AGCC) Software version 4.0 were processed using
OncoScan® Console software version 1.1.034 to pro-
duce OSCHP files and a set of QC metrics. Among the
list of QC metrics generated by OncoScan® Console,
the two most important for the evaluation of assay per-
formance are MAPD and ndSNPQC. For the purpose
of cross-laboratory comparison, samples with “out of
bounds” QC metrics were not excluded as the focus
is on reproducibility across laboratories, regardless
of basal QC level. However, the accuracy of SM
calls is strongly correlated to ndSNPQC, so for the
purpose of Orthogonal SM validation, any samples
that were classed as “out of bounds” according to
the product guidelines (ndSNPQC <26) were excluded.
The remaining samples (OSCHP files) were then ana-
lysed for the concordance of OncoScan® assay SM calls
with pre-validated SM calls and cross-laboratory valid-
ation of the breadth of QC and platform outputs. Ana-
lysis was performed using a set of custom scripts
written in the statistical software programming lan-
guage R, version 3.1.0. Specific analyses were carried
out as follows:
QC comparison
To test the inter-laboratory reproducibility of QC met-
rics, the MAPD distributions of the 3 laboratories were
first compared by a one-way ANOVA. Upon finding any
significant difference at the 5% level a follow up pairwise
test was performed to identify which laboratories did
not have the same MAPD mean. This process was
repeated for ndSNPQC.
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For each triplicate, a set of 3 CN profiles were created,
each CN profile is made up of ~ 220,000 CN probes dis-
tributed across the genome. Each CN profile was simpli-
fied from numerical CN values (e.g. 1,2,3,4,7,9) to CN
Call e.g. (“homozygous loss”, “loss”, “normal diploid”,
“gain”, “high gain”, where “high gain” is defined as CN
>3). For each inter-probe distance across the entire
length of the genome if all three laboratories agree on
the CN Call then that region is said to be in 100% agree-
ment. The percentage of the entire genome for which all
three laboratories agree on the CN Call is reported as
the genome-wide percentage CN Call Agreement. This
was summarised across all triplicates to calculate the
median genome-wide percentage CN Call Agreement.
LOH comparison
For each triplicate, a set of 3 LOH profiles were created,
each LOH profile is made up of ~ 220,000 CN probes
distributed across the genome. For each inter-probe dis-
tance across the entire length of the genome if all three
laboratories agree on the LOH Call then that region is
said to be in 100% agreement. The percentage of the en-
tire genome for which all three laboratories agree on the
LOH Call is reported as the genome-wide percentage
LOH Call Agreement. This was summarised across all
triplicates to calculate the median genome-wide percent-
age LOH Call Agreement.
TuScan comparison
For each triplicate the percentage agreement of ploidy is
calculated (i.e. 0%, 66% or 100%). The mean of all tripli-
cate percentage agreement of ploidy was calculated and
returned as the average percentage agreement of ploidy.
The same process was repeated for aberrant cell fraction
estimates to report the average percentage agreement of
aberrant cell fraction.
SM comparison
SM calls are often closely related to ndSNPQC, for the
purpose of this comparison triplicates for which all
sample runs had ndSNPQC ≥26 (“in-bounds”) were col-
lected. The SM calling software supplied with the
OncoScan® assay translates signal intensity from the ar-
rays into a Mutation Score. To this Mutation Score two
thresholds are applied on an SM by SM basis that clas-
sify Mutation Scores into one SM Call of “Undetected”,
“Lower confidence” or “High confidence”. The SM Calls
used throughout this study are derived from the default
Mutation Score thresholds supplied in the software. On
each triplicate the Mutation Call for each SM was com-
pared between laboratories and the % concordance re-
ported, where concordance is defined as the maximum
of the percentage of samples which agree on Mutationcall. For example where two sample runs agree on a
“high confidence” call and the other sample run returns
a “lower confidence” call the maximum % of samples
that agree with each other is 66%. This flavour of SM
concordance tests only whether replicates across labora-
tories agree, regardless of any pre-validation, sensitivity
in regards to pre-validation is described in the subsequent
section.
Orthogonal SM validation
The colorectal cancer samples provided by LICAP were
pre-validated by pyrosequencing for BRAF:p.V600E:
c.1799T > A and KRAS:p.G12D/V:c.35G > A/T, triplicate
runs of 22 samples each (66 sample runs). The somatic
mutation pre-validation of samples obtained from
WMRGL were performed with Sanger sequencing
(PTEN, TP53, BRAF); pyrosequencing (KRAS, NRAS);
and RT-qPCR (EGFR and PIK3CA). Each SM on the
OncoScan® assay returns a Mutation Score derived
from the signal present on the OncoScan® array. All
pre-validation data was previously initiated outside of
the scope of this study and utilised in this study on an
ad hoc basis. SM Calls were split into three categories;
“Undetected”, “Lower Confidence” and “High Confidence”
predefined by a set of SM specific Mutation Score thresh-
olds. “Lower Confidence” SM Calls were treated as “un-
detected” (negative) for the purpose of calculating
sensitivity.
Single sample clinical analysis
After conversion of CEL files by OncoScan® Console,
OSCHP files were loaded into BioDiscovery's Nexus Ex-
press for OncoScan® for analysis of clinically relevant
CN and LOH events. In parallel SMs were visualised in
Somatic Mutation Viewer and cross referenced with the
CN data for correlation with CN events. Four types of
interesting event were searched for; SM in the presence
of Copy Neutral LOH, common tissue specific amplifica-
tion, general amplifications seen across tissue types and
samples for which there were multiple clinically action-
able amplifications. For this analysis amplifications were
defined as a ratio of “gene of interest”: “baseline for that
genome” of >2.2.
Results
The reproducibility of key CN, LOH, SM and QC met-
rics were evaluated from OncoScan® assay data produced
by the three laboratories on the same 162 samples. The
raw microarray data (CEL files) and processed micro-
array data (OSCHP files) have been made publicly avail-
able via the Array Express database (www.ebi.ac.uk/
arrayexpress) [14] under accession number E-MTAB-
2914. For clarity the results have been subdivided into
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QC comparison
Routine QC metrics are generated during the conversion
of CEL files to OSCHP file by the OncoScan® Console
software. Two metrics are used to classify a sample run
as “in-bounds” or “out of bounds”, these are; Median
Absolute Pairwise Difference (MAPD) and normal
diploid SNP Quality Control (ndSNPQC), for which
descriptions can be found in the List of Abbreviations.
The thresholds for determining “in-bounds” or “out of
bounds” were the defaults supplied by the manufacturer
(MAPD < =0.3 and ndSNPQC > =26 to be classified as
“in-bounds”). Distribution of MAPD between laborator-
ies showed no statistically significant differences at the
5% level (ANOVA). However, it is clear from Figure 1
that properties inherent to the sample have a profound
effect on the MAPD values, likewise for ndSNPQC dem-
onstrated in Figure 2. ANOVA followed by a pairwise
test of ndSNPQC between laboratories showed a statisti-
cally significant difference at the 5% level between
laboratory B and the other two laboratories. This differ-
ence was isolated to the first 56 samples only (TSB IDs
00019-74). Enquiry into the difference between the first
56 and the later 106 samples with the sample source
sites revealed that the first 56 were plated in two inde-
pendent events at laboratory C, with laboratory C and
laboratory A receiving DNA from the first plating event
and laboratory B from the second plating event. TheFigure 1 MAPD of 162 samples ran in triplicate across three laborato
variance is larger than the mean of the intra-sample MAPD variances. Thes
of the samples.remaining 106 samples were all plated in a single plating
event at laboratory C. In order to evaluate the effect on
CN and LOH results we calculated the genome-wide
percentage CN Call agreement for the 56 samples af-
fected by the plating issue on pairs of labs rather than all
three sites. We compared the distribution of genome-
wide percentage CN Call agreement involving the af-
fected Lab B (LabA-LabB and LabB-LabC comparisons)
versus those not involving Lab B (LabA-LabC compari-
son). The resulting test showed no significant difference
between the mean genome-wide percentage CN Call
agreement (p =0.773) and so the effect on CN and LOH
can be considered negligible. Thus for a DNA sample of
a given quality and quantity, the QC metrics remain
stable even when the assay is performed in different la-
boratory setups.
CN/LOH comparison
A set of three CN profiles was plotted for each triplicate
(one for each lab), the percentage CN Call Agreement
along the length of the genome was also plotted and the
genome-wide percentage CN Call agreement calculated
(See Figure 3, See Additional file 2). For all triplicates
the median genome-wide percentage CN Call Agree-
ment was 97%. This indicates that when a sample is run
across 3 laboratories, 97% of the length of the genome
can be expected to agree on the CN Call across all three
laboratories. As part of the three CN plots, LOH calls
were also included (plotted in yellow along the CN
State = ND line). The genome-wide percentage LOH callries with the Affymetrix OncoScan® assay. The inter-sample MAPD
e inter-sample MAPD differences are governed by inherent properties
Figure 2 ndSNPQC of 162 samples ran in triplicate across three laboratories with the Affymetrix OncoScan® assay. The inter-sample
ndSNPQC variance is larger than the mean of the intra-sample ndSNPQC variances. These inter-sample ndSNPQC differences are governed by
inherent properties of the samples. TSBIDs 00019-74 have a markedly lower ndSNPQC in sample-runs performed at laboratory B. Investigating the
source of this difference we identified that the DNA for these samples was plated in two separate events and only laboratory B used plates from
the second plating event.
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median taken across all triplicates to give a median
genome-wide percentage LOH agreement of 99%.
TuScan comparison
During analysis of the CEL files the TuScan algorithm
generates an estimate of tumour ploidy and aberrant cell
fraction. The percentage concordance was calculated for
ploidy and aberrant cell fraction for each triplicate. For
example, if two of the three laboratories agreed that the
ploidy of a sample was 4 then the percentage concord-
ance was 66%. The mean of the set of triplicates where
all sample runs had ndSNPQC ≥ 26 was calculated as
97% for ploidy and 90% for aberrant cell fraction.
SM comparison
Each sample run produces a “High Confidence”, “Lower
Confidence” or “Undetected” call for each of the 74
SMs. The mean percentage concordance of all SMs for
triplicates where all sample runs have ndSNPQC ≥ 26
was 93%. For a detailed summary by SM and ndSNPQC
see Additional file 1: Table S3.
Orthogonal SM validation
Where available, orthogonal SM data was collected from
sample source sites. This data was originally collected as
part of routine clinical diagnostic testing or for the pur-
pose of basic research on samples used here as part ofother studies. No orthogonal SM validation data was
generated expressly for this study. Out of the 74 SMs de-
tectable by the OncoScan® assay, 18 SMs were pre-
validated to be present in at least one sample by an or-
thogonal technology (RT-qPCR, Sanger sequencing or
pyrosequencing). For each SM, all samples pre-validated
to be positive for the SM were collected and the Muta-
tion Score plotted. Since each sample was run at all
three laboratories, every sample has three sample runs,
but only those with ndSNPQC ≥26 (QC metrics in/out
of bounds threshold) are present in the Mutation Score
plots. Of the 18 pre-validated SMs, 2 were present in
large numbers of sample runs; BRAF:p.V600E:c.1799T >
A and KRAS:p.G12D/V:c.35G > A/T; with 73 and 85
sample runs respectively. Figure 4A shows the Mutation
Score of 73 sample runs pre-validated for BRAF:p.
V600E:c.1799T > A. All sample runs exceeded the high
confidence threshold, which resulted in 100% sensitivity
with respect to the pre-validation data. Figure 4B shows
the Mutation Score of 85 sample runs pre-validated for
KRAS:p.G12D/V:c.35G > A/T. Of the 85 pre-validated
sample runs, the OncoScan® assay detected this muta-
tion with a high confidence call in 76 sample runs, with
a lower confidence call in 8 samples runs and as un-
detected in 1 sample run. Considering only the high
confidence calls, the resulting sensitivity with respect to
the pre-validation data was 89%. The sensitivity values
for the remaining 16 pre-validated SMs did not have a
Figure 3 Copy Number profiles for sample TSB000156, with the CN agreement plot. Prior to plotting, numeric CN is translated to CN Call;
“High Loss”, “Loss”, “ND”, “Gain” and “High Gain” with numeric CN conditions; “CN < 1”, ”1≤ CN < 2”, “CN = 2”, “3≥ CN > 2” and “CN > 3”
respectively. Events smaller than 1 Megabase are plotted as dashed lines. Red represents CN gains (dark red is “High Gain”), green represents loss
(dark green is “High loss”). Panels A), B) and C) show the replicate CN profiles of sample TSB000156 run at three independent laboratories.
Regions of LOH are plotted along the CN State = ND line as yellow bars. Panel D) shows the percentage of sites that agree on a given CN event
along the length of the whole genome. GW-CN-Call-Agreement describes the percentage of the length of the genome for which all three
independent laboratories agreed on the CN Call, in this case 94.7%. Similarly for LOH the percentage of the length of the genome for which all
three independent laboratories agreed on LOH status is 99.1%. Noteworthy in this example is the out of bounds ndSNPQC value (<26) producing
remarkably reproducible CN data.
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resolution on the true sensitivity (See Additional file 1:
Table S2). Considering only the higher confidence calls,
the mean sensitivity of all pre-validated SMs, weighted
by the number of sample runs pre-validated for each
SM, interpreted as the overall OncoScan® assay SM sen-
sitivity was 90%.
Copy number, LOH and SM data from each sample
was then analysed in tumour specific batches for pres-
ence of clinically actionable aberrations and other recur-
rent, diagnostic or prognostic mutations. Findings of
particular interest are discussed below.
Discussion
The first objective of this study was to demonstrate the
reproducibility of the OncoScan® assay when run by
operators in different laboratory environments usingclinically relevant FFPE material. Assay reproducibility
was measured by the inter-laboratory agreement of QC
metrics, genomic events such as CN gain/loss, LOH, SM
calls, ploidy and aberrant cell fraction estimates.
Our results showed >90% inter-laboratory agreement
on all the parameters analysed, demonstrating the
robust performance of the OncoScan® assay and its
ability to generate highly reproducible results in a
variety of laboratory setups with differing SOPs. It is
clear from Figures 1 and 2 that intrinsic sample quality
plays the largest part in overall inter-sample QC
differences, with laboratory environment accounting
for little or no difference. This is demonstrated for
MAPD by calculating the mean of within-sample
variances (variance of each triplicate) against the global
variance of all sample-runs, yielding 0.00022 and
0.0025 respectively; an order of magnitude difference.
Figure 4 Marker view of Mutation Score for A) BRAF:p.V600E:
c.1799T > A and B) KRAS:p.G12D/V:c.35G > A/T. Each point
represents a sample, with red points representing a high confidence
calls, blue points representing a low confidence call and grey point
representing an undetected call. The vertical purple lines mark the
lower confidence threshold and the high confidence threshold for
mutation calls. Each box plot indicates the distribution of Mutation
Score for hundreds of normal samples in the universal reference
believed to be absent for that SM. A) Shows the Mutation Scores for
73 samples pre-validated for BRAF:p.V600E:c.1799T > A. The overall
OncoScan® assay high confidence call concordance for BRAF:p.
V600E:c.1799T > A to the pre-validated SM calls is 100%. B) shows
the Mutation Scores for 85 samples pre-validated for KRAS:p.G12D/V:
c.35G > A/T. The overall OncoScan® assay high confidence call
concordance for KRAS:p.G12D/V:c.35G > A/T to the pre-validated SM
calls is 89%.
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datasets was observed for the ndSNPQC metric. Iso-
lated to only the samples plated in two separate events
at laboratory C and run at laboratory B, it is most likely
that this is related to an inconsistency during a sample
re-plating event where laboratory A and laboratory C
received plated DNA from the first plating event and
laboratory B received plated DNA from a second, later
event. The remaining 106 samples, for which all DNA
was plated at the same time at laboratory B, did not
show any significant difference between laboratories.
The low ndSNPQC at laboratory B for the first 56 re-
plated samples points to low DNA input into the assay,
which is in agreement with our previous finding that as
total DNA input decreases below 40ng of the recom-
mended 80ng, so does ndSNPQC. The differences in
ndSNPQC are the most likely explanation for the dis-
crepancies in Mutation Call between laboratories. For
each SM, the Mutation Score is calculated from the sig-
nal on the array and the underlying variability of that
signal in a large reference of samples negative for thatSM. For those samples that have Mutation Scores
closer to the Mutation Score thresholds that define the
boundaries between Mutation Calls (“Undetected”, “Lower
Confidence” and “High confidence”), a slight change in
ndSNPQC could shift the Mutation Score and result in
the change of the SM call from “detected with lower con-
fidence” to “undetected” or from “detected with high con-
fidence” to “detected with lower confidence”. These
thresholds can be adjusted with the Somatic Mutation
Viewer software provided with the OncoScan® assay, enab-
ling more sophisticated classification of somatic mutation
events. The disagreements between laboratories on QC
parameters and aberrant cell fraction were minimal. Ana-
lysis of genome-wide percentage CN Call agreement be-
tween triplicates showed a median of 97% of the length of
the genome of a sample run in triplicate agreed on CN
Call in all three sample runs. By extension, 3% of the
length of the genome showed disagreement in CN Calls
between the three sample runs. This disagreement can be
attributed to three main sources, two of which are related
to the segmentation algorithm; a number of smaller CN
gains/losses are sometimes not called if their Log2Ratios
and supporting BAF data lay close to the calling boundary,
alternatively, small discrepancies in the exact start/end of
a larger segment. The third component of the 3% dis-
agreement occurs when there is a disagreement on the
ploidy of the sample between laboratories. Whilst rare,
when it does occur, disagreement on ploidy results in large
reductions to the genome-wide percentage CN Call agree-
ment and therefore the median across all triplicates. This
effect is substantially reduced by manual curation of the
data which is made possible by the Nexus Express for
OncoScan® software. Genome-wide percentage LOH
call agreement showed an average 98% of the length of
a genome of a sample run in triplicate across three la-
boratories will agree in LOH call in all three sample
runs. The discrepancy is almost entirely explained by
small disagreements on the exact start/end of large
LOH segment. It is important to note that review of
log2ratio pattern by an experienced analyst allows for
correction of copy number calls by the algorithm and
clinically actionable findings such as biallelic losses or
regions of high amplifications can be unambiguously
identified by the user. Some level of disagreement is to
be expected when dealing with complex algorithms
determining discrete results from continuous data and
ploidy is no exception. Our reproducibility data showed
3% of triplicates did not unanimously agree on the ploidy.
The TuScan algorithm estimates ploidy and aberrant
cell fraction simultaneously, determining the most likely
solution that fits the observed aberrations in the data.
The most likely ploidy and aberrant cell fraction (that
best explains the data) is then reported. Rarely (in 3% of
the triplicates) there are 2 solutions that fit the data
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chosen over another in some of the replicates.
The second objective of this study was to demonstrate
the validity of the OncoScan® assay in the detection of
SMs by using clinical samples pre-validated for a set of
SMs by other technologies. To make this assay more re-
liable to clinical standards, any SMs detected as “lower
confidence” were considered undetected. It should be
appreciated that in using our stringent approach to som-
atic mutation calling, any pre-validation errors (false
positives) by other technologies would become false neg-
atives in our analysis and lead to underestimation of the
sensitivity figures. Of the 9 sample runs pre-validated for
KRAS:p.G12D/V:c.35G > A/T with “lower confidence” or
“undetected” calls by the OncoScan® assay, 6 have an ab-
errant cell fraction <20% (TuScan aberrant cell fraction
call is “homogeneous”, CN events evident but reduced
evidence in BAF data). The 3 remaining sample runs are
all from a single sample: TSB00053 which does not have
a low aberrant cell fraction. Analysing these 3 sample
runs in isolation shows that while the Mutation Score is
not high enough to exceed the “lower/high confidence”
mutation score threshold and constitute a confident call,
KRAS:p.G12D/V:c.35G > A/T is the highest scoring SM
in all three sample runs. According to the pyrosequenc-
ing pre-validation, this SM was present at 16%. This is
in line with the OncoScan® assay product specification
of a minimum 20%-25% SM in wild type for the reliable
detection of somatic mutations. The CN events for this
sample are at much higher frequency than 16%, indicat-
ing some level of intra tumour heterogeneity where a
minor clone has gained a KRAS:p.G12D/V:c.35G > A/T
SM. Again, the Mutation Score thresholds that define
the boundaries of mutation call can be manually ad-
justed in the software to accommodate for out of bounds
QC or aberrant cell fraction and in future may lead to
more sophisticated SM calling.
Data generated from this validation study were also
analysed for identification of SM and CN aberrations of
potential clinical relevance for patient stratification or
application of targeted therapeutics. Highlighted here
are a selection of examples that illustrate the benefits of
CN, LOH and SM results from a single platform that
can be applied across multiple cancer types.
An ability to identify acquired Copy Number Neutral
LOH (CNNLOH) across the whole genome is a key
feature of this assay. CNNLOH, sometimes referred to
as acquired isodisomy or acquired uniparental disomy
(aUPD), has been frequently described in haematological
malignancies [15-18] and also in the study of solid tu-
mours [19-21]. This mechanism has been associated
with duplication of oncogenic mutations as well as loss
of the wild-type allele in the presence of tumour-
suppressor mutations. LOH in the region surroundingTP53 is commonly reported across neoplasms [20,22,23].
In our results, CNNLOH was observed across tumour
types with particular recurrence in regions of known
key tumour suppressor genes such as PTEN and
TP53. The multiform nature of data derived from the
OncoScan® assay adds considerable value to these
samples with regions of CNNLOH frequently observed
as co-occurring with SMs in both oncogenes and
tumour suppressor genes across tumour types. The
ability to identify both phenomena through the use of
a single assay enables accurate genomic profiling for
rapid patient stratification. Concurrent CNNLOH of
17p regions (including TP53) together with known,
clinically significant TP53 mutations were observed in
colorectal, lung, ovarian and breast cancer samples
examined during our study (see Figure 5). Deletion of
17p was also a common finding across the samples
examined. This data allows for rapid confirmation of
the second hit of LOH in the presence of a SM as re-
moving the wild-type allele and therefore contributing
to the development of the cancer genomes in these pa-
tients. Biallelic inactivation of TP53 is proposed as a
positive predictor for multiple targeted therapies cur-
rently being trialled, as summarised in the TARGET
database compiled by van Allen et al [24].
Regions of High Focal Amplification (HFA) were fre-
quently observed across tumour types and accurately
quantified in a whole genome context by the OncoScan®
assay. Many of these aberrations were specific to the
primary tissue of origin of the cancer, for example, lung
developmental transcription factor NKX2-1 in lung can-
cer [25], AURKA in colon cancer [26] and AR in prostate
cancer [27]. Conversely, several others were observed
across cancer types, highlighting cross-cancer similar-
ities. AKT2 amplification, potentially predicting sensitiv-
ity to AKT/MTOR inhibitors [28], was highly amplified
in breast, lung and ovarian cancer samples in our data-
set. ERBB2 (HER2) amplification, predicting sensitivity
to anti-HER2 therapy [29] was also observed in our cohort
in breast, colorectal, lung and ovarian cancer samples.
CCND1 at 11q13, a well-documented region of high amp-
lification [30], represented the gene most commonly in-
volved in HFA in our dataset, across multiple tumour
types. CCND1 focal amplification was observed in samples
from patients with breast cancer, melanoma and ovarian
cancer. CCND1 most specifically represented the most
common focal amplification in the breast cancer patients
analysed, 12/28 (43%) (see Figure 6). Such cross-cancer
similarity and recurrence of targetable aberrations high-
lights the potential for increased cross-cancer therapeutics
and argues for re-classification of some tumours away
from primary tissue of origin and towards a system based
on the biological pathways that are mutated in the cancer
genome.
Figure 5 Whole chromosome 17 CN trace from breast cancer sample TSB00095. The figure is captured by the Nexus Express for Affymetrix
software version 3. A) is a karyoview of the chromosome where the blue bar represents a gain and the annotation tracks below highlight genes
and other genomic features of interest. B) is the log2ratio plot and C) the BAF plot. It shows CNNLOH of the entire chromosome with duplication
of the distal region of the long arm of chromosome 17. This patient also has a TP53:p.R213*:c.637C > T SM at 17p13.1 annotated as a red star
on karyoview.
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scape of cancer genomes is that the genomic findings are
often extremely complex, with frequent co-occurrence of
targetable aberrations. An example of this is observed in
sample number TSB00115 that shows multiple regions of
high amplification, including regions listed in the TAR-
GET database [24]: High focal amplification of CCND1,
FGFR1 andMDM4 are all observed in a complex genomic
setting that also includes whole arm amplification of 8q,
including MYC (see Figure 7). In such instances, single
target treatments may not be appropriate, it is importantFigure 6 Multi-sample comparison of 28 different breast cancer samp
genome view of the CN events captured by the Nexus Express for Affymet
which denotes the percentage of samples that contain focal amplification
traces. The blue lines denote a region of focal amplification. Focal amplifica
chromosome 11.that we can observe the entire aberration landscape to
make informed decisions on not only what treatments op-
tions are available, but also how they might best be used
in combination.
Conclusions
Effective therapeutic intervention requires an understand-
ing of the global genomic changes that drive tumour
growth and the interplay between altered metabolic/sig-
nalling pathways. The low quantities of DNA available
from FFPE together with the time and costs associatedles with focal amplification of CCND1. The figure is a whole
rix software version 3. A) Is the aggregate plot for these 28 samples
in a region. B) Depicts a set of single sample focal amplification event
tion of CCND1 is visible on the first 12 out of 28 samples on
Figure 7 Whole genome CN trace from breast cancer sample TSB00115. Captured by the Nexus Express for Affymetrix software version
3. A Complex cancer genome is shown from a patient with breast cancer. Upper panel is the log2ratio plot and lower panel is the BAF plot.
Multiple aberrations are observed across the genome, including high focal amplifications of the proposed predictive genes: CCND1, FGFR1
and MDM4.
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need for multiplexing technologies that allow a
broader view of the whole cancer genome from one
test, ensuring that patients are diagnosed, stratified ap-
propriately and that correct therapies are employed in
clinically relevant timeframes. A single test that de-
livers accurate whole genome CN data, with high reso-
lution in cancer genes and high dynamic range
detection capabilities alongside a panel of frequently
tested SMs is a valuable development with potential
clinical utility. We have demonstrated that the OncoS-
can® assay provides reproducible SM, CN, LOH, and
QC metrics irrespective of laboratory environment.
We have shown how OncoScan® can detect all known
actionable copy number alterations in a single assay
with high sensitivity, as well as provide an assessment
on genomic instability. Furthermore, we have shown
that there is > 90% agreement of somatic mutation calls
between the OncoScan® assay and sequencing tech-
nologies currently widely employed. This validation of
CN, LOH and SM reproducibility supports its potential
adoption as a clinical diagnostic tool.
Future work will look to further validate SM sensitivity
and specificity against NGS approaches for a wider set
of the SM panel covered by the OncoScan® assay. A
comparison of CN data concordance with orthogonal
array, FISH and NGS approaches will be useful for de-
termining CN event boundary accuracy along with lower
resolution comparisons to the current routine test forthe detection of CN aberrations; FISH. In addition to
platform validation, this data set has provided unique
insight into genomic events in a wide range of tumour
types that will form the basis of future follow up studies.
Additional files
Additional file 1: Table S1. Shows the 162 unique samples used for
analysis in this report, the laboratory from which they were sourced, the
primary tumour type, the tissue of origin, any somatic mutation the sample
was pre-validated for and the technology used for that pre-validation.
Table S2. Shows the number of sample runs with ndSNPQC ≥ 26
pre-validated for each somatic mutation. For each somatic mutation
the number of true positives (sample runs pre-validated for the SM
that record it as a “High Confidence” Call by the OncoScan® assay),
false negatives (sample runs pre-validated for the SM that record it as
a “Lower Confidence” or “Undetected” Call by the OncoScan® assay)
and the Sensitivity (true positives/(true positives + false negatives)).
Table S3. Shows the concordance of the 64 Somatic Mutations (SMs)
available on the OncoScan® assay. SM performance is closely related
to the QC metric ndSNPQC. 162 unique samples run in triplicate were
analysed and for the purpose of this analysis split into 3 groups;
triplicates for which all sample runs had ndSNPQC > =35, triplicates for
which all sample runs had ndSNPQC > =26 and triplicates for which all
sample runs had ndSNPQC <26. Supplementary data –The full microarray
dataset are publically available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-2914.
Additional file 2: For each sample run in triplicate (once at each of
the three test laboratories) the CN/LOH profile is plotted alongside
a CN agreement plot that displayed the % of the 3 samples that
agree on a given CN event.
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ND: Normal Diploid; WMRGL: West Midlands Regional Genetics Laboratory;
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SOP: Standard Operating Procedure; MAPD: Median of the Absolute Values of
all Pairwise Differences is a global measure of the variation of all microarray
probes across the genome. It represents the median of the distribution of
changes in log2 ratio between adjacent probes. Since it measures differences
between adjacent probes, it is a measure of short-range noise in the microarray
data. Lower MAPD values are better, with those exceeding 0.30 being
considered “out of bounds”. Further information can be found in the OncoScan®
Console Manual at http://www.affymetrix.com/support/downloads/manuals/
oncoscan_console_1_1_user_manual.pdf; SNPQC: Single Nucleotide
Polymorphism Quality Control is a measure of how well the genotype alleles are
resolved in the micro array data. ndSNPQC is the same metric as SNPQC but only
applied to markers pre-classified as normal diploid (those that have been
determined to have Copy Number equal to two in the sample). Larger
ndSNPQC values are better, where samples with ndSNPQC less than 26 being
considered “out of bounds”. Further information can be found in the OncoScan®
Console Manual http://www.affymetrix.com/support/downloads/manuals/
oncoscan_console_1_1_user_manual.pdf; Mutation Score: Mutation Score is a
measure of the signal intensity of the marker relative to the expected signal
distribution of this marker in the absence of the mutation. A higher Mutation
Score for the same marker indicates greater confidence that the mutation is
present, and is correlated with higher % mutant allele; Mutation Call: For each
SM a pair of thresholds exists that classifies a Mutation Score into one of three
Mutation Call categories: “undetected”, “low confidence” and “high confidence”.
SMs with a Mutation Score less than the low confidence threshold are classified
as undetected. SMs with a Mutation Score higher than the high confidence
threshold are classified as high confidence. SMs with a Mutation Score between
the low and high confidence threshold are classified as low confidence;
Sensitivity: True positives/(true positives + false negatives); Concordance: Max
(number of observations in agreement) /number of observations; Inter-probe
distance: The number of base pairs between two adjacent probes;
TuScan: Analysis algorithm to determine copy number for samples processed
using OncoScan® FFPE Assay Kit; Aberrant Cell Fraction: An output of the
TuScan algorithm, this is the estimated percentage tumour cells in a sample.
When returned as “homogeneous” this is interpreted as either 100% tumour or
100% normal depending upon the supporting CN data.
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